243 related articles for article (PubMed ID: 33121133)
1. Transient Improvement after Switch to Low Doses of RimabotulinumtoxinB in Patients Resistant to AbobotulinumtoxinA.
Hefter H; Samadzadeh S; Moll M
Toxins (Basel); 2020 Oct; 12(11):. PubMed ID: 33121133
[TBL] [Abstract][Full Text] [Related]
2. Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis.
Hefter H; Spiess C; Rosenthal D
J Neural Transm (Vienna); 2014 May; 121(5):513-9. PubMed ID: 24311063
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.
Brin MF; Lew MF; Adler CH; Comella CL; Factor SA; Jankovic J; O'Brien C; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
Neurology; 1999 Oct; 53(7):1431-8. PubMed ID: 10534247
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
Pappert EJ; Germanson T;
Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of botulinum neurotoxin type A injections in naïve and previously-treated patients suffering from Torti- or Laterocollis or -caput: Results from a German-Austrian open-label prospective post-marketing surveillance study.
Jost WH; Schramm A; Müngersdorf M; Stenner A; Schwingenschuh P; Maisonobe P; Koch M; Haslinger B
J Neurol Sci; 2019 Apr; 399():44-50. PubMed ID: 30771702
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure.
Dressler D; Bigalke H; Benecke R
J Neurol; 2003 Aug; 250(8):967-9. PubMed ID: 12928917
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
Brashear A; Lew MF; Dykstra DD; Comella CL; Factor SA; Rodnitzky RL; Trosch R; Singer C; Brin MF; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
Neurology; 1999 Oct; 53(7):1439-46. PubMed ID: 10534248
[TBL] [Abstract][Full Text] [Related]
8. The impact of the initial severity on later outcome: retrospective analysis of a large cohort of botulinum toxin naïve patients with idiopathic cervical dystonia.
Hefter H; Samadzazeh S; Rosenthal D
J Neurol; 2021 Jan; 268(1):206-213. PubMed ID: 32761340
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of abobotulinumtoxinA (Dysport) and onabotulinumtoxinA (Botox) for managing spasticity of the upper and lower limbs, and cervical dystonia.
Danchenko N; Johnston KM; Whalen J
J Med Econ; 2022; 25(1):919-929. PubMed ID: 35730362
[TBL] [Abstract][Full Text] [Related]
10. Clinical differences between botulinum neurotoxin type A and B.
Bentivoglio AR; Del Grande A; Petracca M; Ialongo T; Ricciardi L
Toxicon; 2015 Dec; 107(Pt A):77-84. PubMed ID: 26260691
[TBL] [Abstract][Full Text] [Related]
11. Botulinum Toxin Utilization, Treatment Patterns, and Healthcare Costs Among Patients with Spasticity or Cervical Dystonia in the US.
Hull M; Anupindi VR; DeKoven M; He J; Bouchard J
Adv Ther; 2023 Sep; 40(9):3986-4003. PubMed ID: 37414904
[TBL] [Abstract][Full Text] [Related]
12. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).
Truong DD; Cullis PA; O'Brien CF; Koller M; Villegas TP; Wallace JD
Mov Disord; 1997 Sep; 12(5):772-5. PubMed ID: 9380065
[TBL] [Abstract][Full Text] [Related]
13. Cervical dystonia: factors deteriorating patient satisfaction of long-term treatment with botulinum toxin.
Marciniec M; Szczepańska-Szerej A; Rejdak K
Neurol Res; 2020 Nov; 42(11):987-991. PubMed ID: 32693754
[TBL] [Abstract][Full Text] [Related]
14. The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia.
Hefter H; Schomaecker I; Schomaecker M; Rosenthal D; Samadzadeh S
Toxins (Basel); 2021 Jul; 13(7):. PubMed ID: 34357965
[TBL] [Abstract][Full Text] [Related]
15. The clinical utility of botulinum toxin injections targeted at the motor endplate zone in cervical dystonia.
Delnooz CC; Veugen LC; Pasman JW; Lapatki BG; van Dijk JP; van de Warrenburg BP
Eur J Neurol; 2014 Dec; 21(12):1486-e98. PubMed ID: 25060697
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials.
Chinnapongse RB; Lew MF; Ferreira JJ; Gullo KL; Nemeth PR; Zhang Y
Clin Neuropharmacol; 2012; 35(5):215-23. PubMed ID: 22932474
[TBL] [Abstract][Full Text] [Related]
17. Lessons about Botulinum Toxin A Therapy from Cervical Dystonia Patients Drawing the Course of Disease: A Pilot Study.
Hefter H; Schomaecker I; Schomaecker M; Ürer B; Brauns R; Rosenthal D; Albrecht P; Samadzadeh S
Toxins (Basel); 2023 Jun; 15(7):. PubMed ID: 37505701
[TBL] [Abstract][Full Text] [Related]
18. Adverse events with botulinum toxin treatment in cervical dystonia: How much should we blame placebo?
Duarte GS; Rodrigues FB; Ferreira JJ; Costa J
Parkinsonism Relat Disord; 2018 Nov; 56():16-19. PubMed ID: 29910156
[TBL] [Abstract][Full Text] [Related]
19. The Use of High Initial Doses of Botulinum Toxin Therapy for Cervical Dystonia Is a Risk Factor for Neutralizing Antibody Formation-A Monocentric Cross-Sectional Pilot Study.
Hefter H; Schomaecker I; Schomaecker M; Rosenthal D; Samadzadeh S
Medicina (Kaunas); 2022 Jan; 58(1):. PubMed ID: 35056396
[No Abstract] [Full Text] [Related]
20. KinesioTaping after botulinum toxin type A for cervical dystonia in adult patients.
Dec-Ćwiek M; Porębska K; Sawczyńska K; Kubala M; Witkowska M; Zmijewska K; Antczak J; Pera J
Brain Behav; 2022 Apr; 12(4):e2541. PubMed ID: 35238494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
